Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's PALMAZ-SCHATZ STENT SHOWS CONTINUED RESTENOSIS REDUCTION

This article was originally published in The Gray Sheet

Executive Summary

J&J's PALMAZ-SCHATZ STENT SHOWS CONTINUED RESTENOSIS REDUCTION compared to balloon angioplasty in one-year follow-up results from the Stent Restenosis (STRESS) study. Of the 205 patients randomized for treatment via Johnson & Johnson Interventional Systems' Palmaz-Schatz stent implantation, 10.2% required target lesion revascularization (coronary artery bypass surgery or repeat angioplasty) within one year. This figure compared to an 18.4% rate in the 202-patient group receiving percutaneous transluminal coronary angioplasty. The STRESS researchers said that the continued trend of fewer events in the stent group is "concordant with the reduced restenosis rates" associated with stenting.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT003157

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel